Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

27.07 +0.06 (+0.22%)

Streaming Delayed Price Updated: 1:11 PM EST, Feb 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,187,060
Open	27.69
Bid (Size)	27.06 (100)
Ask (Size)	27.09 (100)
Prev. Close	27.01
Today's Range	24.87 - 27.71
52wk Range	11.75 - 31.77
Shares Outstanding	50,241,789
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Arcutis (ARQT) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Arcutis (ARQT) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Surpasses Q4 Estimates and Raises 2026 Sales Outlook ↗

February 25, 2026

Via Chartmill

Performance

YTD	-6.7%	-6.7%
1 Month	+2.8%	+2.8%
3 Month	-12.6%	-12.6%
6 Month	+73.0%	+73.0%
1 Year	+121.9%	+121.9%

More News

Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 25, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments

February 24, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows Technical Breakout Setup ↗

February 13, 2026

Via Chartmill

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows High-Growth Momentum and Strong Technical Setup ↗

February 11, 2026

Via Chartmill

This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit ↗

February 06, 2026

Via The Motley Fool

Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis

February 02, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa

January 26, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions

January 21, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones

January 12, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Biotherapeutics (NASDAQ:ARQT) Combines High-Growth Momentum with Bullish Technical Setup ↗

December 30, 2025

Via Chartmill

Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares ↗

December 23, 2025

Via The Motley Fool

Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears ↗

December 23, 2025

Via The Motley Fool

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

Via MarketMinute

This Biotech Stock Could Cure Your Portfolio's Pain ↗

December 14, 2025

Via The Motley Fool

ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Shows Strong Technical and Fundamental Momentum ↗

December 11, 2025

Via Chartmill

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

December 08, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Why Shares in Arcutis Biotherapeutics Surged Again This Week ↗

November 21, 2025

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

November 17, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest ↗

November 13, 2025

Via Benzinga

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

November 13, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Strong Trend with High-Growth Momentum ↗

November 10, 2025

Via Chartmill

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

November 04, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Arcutis Biotherapeutics, Inc. - Common stock publicly traded?

Yes, Arcutis Biotherapeutics, Inc. - Common stock is publicly traded.

What exchange does Arcutis Biotherapeutics, Inc. - Common stock trade on?

Arcutis Biotherapeutics, Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock?

The ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock is ARQT on the Nasdaq Stock Market

What is the current price of Arcutis Biotherapeutics, Inc. - Common stock?

The current price of Arcutis Biotherapeutics, Inc. - Common stock is 27.07

When was Arcutis Biotherapeutics, Inc. - Common stock last traded?

The last trade of Arcutis Biotherapeutics, Inc. - Common stock was at 02/26/26 01:11 PM ET

What is the market capitalization of Arcutis Biotherapeutics, Inc. - Common stock?

The market capitalization of Arcutis Biotherapeutics, Inc. - Common stock is 1.36B

How many shares of Arcutis Biotherapeutics, Inc. - Common stock are outstanding?

Arcutis Biotherapeutics, Inc. - Common stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.